Tero Satomaa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tero Satomaa has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Juhani Saarinen
Glykos Finland Oy, Helsinki, Finland
76 shared publications - Jukka O. Hiltunen
Glykos Finland Oy, Helsinki, Finland. 1
74 shared publications - Anna-Liisa Hänninen
Glykos Finland Oy, Helsinki, Finland. 1
73 shared publications - Annamari Heiskanen
Glykos Finland Oy, Helsinki, Finland. 1
73 shared publications - Henna Pynnönen
Glykos Finland Oy, Helsinki, Finland. 1
73 shared publications - Jari Helin
Glykos Finland Oy, Helsinki, Finland. 1
73 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Ex vivo cytotoxicity assays with leukemia blast samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Ex vivo cytotoxicity assays with leukemia blast samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Characterization of LN-mcvc-MMAE DAR4 (lintuzumab vedotin).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Characterization of LN-mcvc-MMAE DAR4 (lintuzumab vedotin).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Characterization of overconjugated GLK-33 batch in rat tolerability and toxicokinetic study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Characterization of overconjugated GLK-33 batch in rat tolerability and toxicokinetic study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mcvc-MMAE DAR4 (lintuzumab vedotin) by cynomolgus monkey liver microsomes at pH 4.5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Digestion of lintuzumab-mcvc-MMAE DAR4 (lintuzumab vedotin) by cynomolgus monkey liver microsomes at pH 4.5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum T-MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Individual and mean serum T-MMAU toxicokinetic parameters following three i.v. bolus doses of T-mavg-MMAU DAR4 in male cynomolgus monkeys.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Mean plasma MMAE toxicokinetic estimates following weekly i.v. doses of free MMAE to Sprague-Dawley rats.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Mean plasma MMAE toxicokinetic estimates following weekly i.v. doses of free MMAE to Sprague-Dawley rats.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Properties and IC50 values of leukemia cell lines and patient samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Properties and IC50 values of leukemia cell lines and patient samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of T-mavg-MMAU DAR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Lysosomal degradation of T-mavg-MMAU DAR8.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Pharmacokinetic parameters of single i.v. dose mouse xenograft tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Pharmacokinetic parameters of single i.v. dose mouse xenograft tumor models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Effect of cysteine protease inhibitor E-64 on lysosomal degradation of T-mavg-MMAU DAR8.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Effect of cysteine protease inhibitor E-64 on lysosomal degradation of T-mavg-MMAU DAR8.